These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 20522531)

  • 1. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
    Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
    J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
    Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS
    J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.
    Dehnhardt CM; Venkatesan AM; Delos Santos E; Chen Z; Santos O; Ayral-Kaloustian S; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Chaudhary I; Yu K; Gibbons J; Abraham R; Mansour TS
    J Med Chem; 2010 Jan; 53(2):798-810. PubMed ID: 19968288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High glucose regulates cyclin D1/E of human mesenchymal stem cells through TGF-beta1 expression via Ca2+/PKC/MAPKs and PI3K/Akt/mTOR signal pathways.
    Ryu JM; Lee MY; Yun SP; Han HJ
    J Cell Physiol; 2010 Jul; 224(1):59-70. PubMed ID: 20232305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies.
    Bursavich MG; Brooijmans N; Feldberg L; Hollander I; Kim S; Lombardi S; Park K; Mallon R; Gilbert AM
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2586-90. PubMed ID: 20303263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
    Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.
    Grzmil M; Morin P; Lino MM; Merlo A; Frank S; Wang Y; Moncayo G; Hemmings BA
    Cancer Res; 2011 Mar; 71(6):2392-402. PubMed ID: 21406405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
    Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus.
    Tups A; Anderson GM; Rizwan M; Augustine RA; Chaussade C; Shepherd PR; Grattan DR
    J Neuroendocrinol; 2010 Jun; 22(6):534-42. PubMed ID: 20236230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck.
    Liu FY; Zhao ZJ; Li P; Ding X; Zong ZH; Sun CF
    Br J Oral Maxillofac Surg; 2010 Jun; 48(4):291-6. PubMed ID: 19615795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates.
    Dekter HE; Romijn FP; Temmink WP; van Pelt J; de Fijter JW; Smit NP
    Anal Biochem; 2010 Aug; 403(1-2):79-87. PubMed ID: 20417611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 16-Hydroxycleroda-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis.
    Lin YH; Lee CC; Chan WL; Chang WH; Wu YC; Chang JG
    Toxicology; 2011 Jul; 285(1-2):72-80. PubMed ID: 21530604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.